Press Releases

Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2021-04-07T21:45:36-05:00

DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer, today announced the closing of its previously announced initial public offering of 18,400,000 shares of common stock, including the full exercise [...]

Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares2021-04-07T21:45:36-05:00

TCR2 Therapeutics Prices IPO Of 5 Mln Shares At $15.00/shr

2019-03-07T11:12:58-06:00

(RTTNews) Feb 13, 2019 - TCR2 Therapeutics Inc. (TCRR) said that it priced its initial public offering of 5 million shares of common stock at a public offering price of $15.00 per share, for aggregate gross proceeds of $75.0 million, before deducting underwriting discounts and commissions and offering expenses. The company has also granted the [...]

TCR2 Therapeutics Prices IPO Of 5 Mln Shares At $15.00/shr2019-03-07T11:12:58-06:00

iTeos Therapeutics Completes $75 Million Series B Financing

2018-06-20T10:17:50-05:00

- Oversubscribed financing round led by new U.S. investor MPM Capital - Proceeds to support accelerated development of innovative next-generation immuno-oncology pipeline into the clinic and the company’s expansion into the U.S. Gosselies, Belgium – June 20, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the completion of an [...]

iTeos Therapeutics Completes $75 Million Series B Financing2018-06-20T10:17:50-05:00

TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing

2019-03-07T11:13:14-06:00

Proceeds will support clinical development of lead program TC-210 and expansion of the multi-format TRuC™-T cell pipeline in solid tumors and blood cancers CAMBRIDGE, Mass., March 21, 2018 /PRNewswire/ -- TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today [...]

TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing2019-03-07T11:13:14-06:00
Go to Top